Abstract:Objective: To construct a kind of paclitaxel-loaded long-circulating nanoliposomes actively targeting lung tumor in order to improve the tissue distribution of paclitaxel in vivo, and to promote the safety and the anti-tumor efficacy of paclitaxel administration. Methods: The complex of arginine glycine-aspartic acid-e-amino hexanoic acid linker-palmitate (RGD-EACA-Pal) was synthesized by solid-phase synthesis method. The sterically stabilized liposome of paclitaxel (SSL-PTX) and the active lung cancer-targeting sterically stabilized liposome of paclitaxel (T-SSL-PTX) were prepared by thin film ultrasonication-dispersion method, respectively. The pharmacokinetics, tissue distribution and the anti-tumor effects of two different formulations of paclitaxel were evaluated after intravenous injection of taxol, SSL-PTX or T-SSL-PTX in tumor-bearing nude mice. The maximum tolerance doses (MTDs) of two different formulations of paclitaxel were determined in Kunming mice. Results: Transmission electron microscopy (TEM) image showed that both SSL-PTX and T-SSL-PTX shaped regularly round and dispersed uniformly, and these two particle sizes were (83.4±36.7) nm and (94.7±41.2) nm, respectively. The encapsulation efficiencies of both SSL-PTX and T-SSL-PTX were at or above 95%. In vivo, the circulation time of SSL-PTX or T-SSL-PTX was longer than taxol, and the pharmacokinetic parameters of SSL-PTX and T-SSL-PTX were similar. Tumor-targeting efficiency of T-SSL-PTX was better than that of SSL-PTX or taxol, as well as the tissue distribution of T-SSL-PTX in normal organs was at a relatively low level as compared with that of SSL-PTX or taxol, in contribution to RGD specifically targeting tumors. The MTDs of SSL-PTX and T-SSL-PTX were higher than that of taxol. Compared with SSL-PTX and taxol with the same dose of paclitaxel, the anti-tumor efficacy of T-SSL-PTX was improved significantly (P＜0.05); and the mice received T-SSL-PTX therapy with a longer interval or at a lower dose also achieved significant tumor growth retardation.Conclusion: The lung cancer-targeting long-circulating nanoliposomes of paclitaxel may increase the safety and anti-tumor efficacy of paclitaxel through improving its pharmacokinetics and tissue distribution in vivo. DOI:10.3781/j.issn.1000-7431.2011.03.004

FV-429 Enhances the Efficacy of Paclitaxel in NSCLC by Reprogramming HIF-1α-modulated FattyAcid Metabolism

Influence of C-Src on Hypoxic Resistance to Paclitaxel in Human Ovarian Cancer Cells and Reversal of FV-429

The Anti-Tumor Effects of Lung Cancer-Targeting Long-Circulating Paclitaxel-Containing Liposomes

Integrin-targeted paclitaxel nanoliposomes for tumor therapy

FGFR Inhibitors Combined with Nab-Paclitaxel - A Promising Strategy to Treat Non-Small Cell Lung Cancer and Overcome Resistance

FATS inhibits the Wnt pathway and induces apoptosis through degradation of MYH9 and enhances sensitivity to paclitaxel in breast cancer

Targeting HDAC with a Novel Inhibitor Effectively Reverses Paclitaxel Resistance in Non-Small Cell Lung Cancer Via Multiple Mechanisms

FV-429 induces autophagy blockage and lysosome-dependent cell death of T-cell malignancies via lysosomal dysregulation

Role of Focal Adhesion Kinase in Regulating Yb-1-Mediated Paclitaxel Resistance in Ovarian Cancer

Overcoming the hypoxia-induced drug resistance in liver tumor by the concurrent use of apigenin and paclitaxel.

Synergistic Inhibition of Breast Cancer by Co-Delivery of Vegf Sirna and Paclitaxel Via Vapreotide-Modified Core-Shell Nanoparticles

A novel pan class-I glucose transporter inhibitor DRB18 exhibits synergistic effects in vitro and in vivo with paclitaxel against human non-small cell lung cancer

FV-429 induces apoptosis by regulating nuclear translocation of PKM2 in pancreatic cancer cells

Preparation, characterization, and antitumor activity of paclitaxel-loaded folic acid modified and TAT peptide conjugated PEGylated polymeric liposomes.

Improved Tumor-Targeting Drug Delivery and Therapeutic Efficacy by Cationic Liposome Modified with Truncated Bfgf Peptide.

The Anticancer Efficacy of Paclitaxel Liposomes Modified with Low-Toxicity Hydrophobic Cell-Penetrating Peptides in Breast Cancer: an in Vitro and in Vivo Evaluation

The Novel Triazolonaphthalimide Derivative Lss-11 Synergizes The Anti-Proliferative Effect Of Paclitaxel Via Stat3-Dependent Mdr1 And Mrp1 Downregulation In Chemoresistant Lung Cancer Cells

Anti-tumor activity of paclitaxel through dual-targeting lipoprotein-mimicking nanocarrier.

Glycolysis Inhibition and Apoptosis Induction in Human Prostate Cancer Cells by FV-429-mediated Regulation of AR-AKT-HK2 Signaling Network

FV-429 Induces Apoptosis and Inhibits Glycolysis by Inhibiting Akt-mediated Phosphorylation of Hexokinase II in MDA-MB-231 Cells

GPRC5A promotes paclitaxel resistance and glucose content in NSCLC